A 49% capex spike and a lost bidding war cratered Dutch Bros shares, but one analyst just reloaded his Buy rating while shifting his valuation two years forward. The question is whether slowing foot…
Anthropic filed confidentially for an IPO at a valuation that would place it above some of the most established names in tech, yet its financials raise hard questions about whether public markets will price…
Tesla and SpaceX reported the same strategy this summer: spend aggressively now and collect profits later. A simultaneous market selloff would punish Elon Musk's fortune from both sides, and the two companies face that…
Coca-Cola has beaten earnings five straight quarters and raised its guidance, yet a pending IRS ruling and a price-to-free-cash-flow ratio of 71 hang over the stock like a storm cloud. Here is what the…
Palo Alto Networks CEO Nikesh Arora said something on the earnings call that most tech executives only whisper, and it tells you exactly why one investor keeps adding to his position despite a nine-figure…
Most investors write off the Nasdaq-100 as a dividend wasteland, but a handful of its chip and networking giants have been quietly raising their payouts every single year while competitors chase hype cycles.
Cloudflare has surged nearly 80% this year on the back of an AI security boom, but the stock now trades at a multiple that punishes any stumble. The next two earnings reports will determine…
Tesla just posted record deliveries and still trades at 344 times earnings while Rivian bleeds cash but actually gets valued like a car company. The gap between those two realities reveals something uncomfortable about…
With Treasury yields climbing past 5% and both utility giants sliding in price, picking the wrong one for your retirement portfolio could cost you years of lost income or growth. The answer depends entirely…
Adobe's stock has collapsed while its revenue keeps hitting records, and Wall Street is stuck in a holding pattern. A specific combination of catalysts could change that calculus dramatically before 2027 is over.
Insurance brokers collect commissions whether rates rise or fall, but three companies have quietly turned that boring renewal cycle into something that looks a lot like a compounding machine. The question is whether falling…
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to AI infrastructure.…
Bitcoin has swung 44% in three months yet sits 25% below where it stood a year ago, and the strategy most newcomers swear by may actually cost them more than they realize depending on…
Meta is spending more than a hundred billion dollars on AI while free cash flow has cratered and earnings missed expectations, yet a five-year price model still sees your stake growing substantially. The question…
